accountMarch 24 (Bloomberg) -- A GlaxoSmithKline Plc lawyer told a federal court jury that Abbott Laboratories sought to stifle competition and maintain an illegal monopoly over HIV drugs when it quadrupled the price of its AIDS medicine Norvir in 2003. Glaxo...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Glaxo Accuses Abbott of Stifling Competition on AIDS Drug
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account